A team of researchers from Michigan Medicine found a new purpose for epigenetic drugs and a potential treatment option for patients with scleroderma. This chronic disease affects the immune system, causing a buildup of scar-like tissues in the skin and internal organs known as fibrosis. Pen-Suen Tsou (Eliza), Ph.D., senior author and a rheumatology researcher at Michigan Medicine, explains how this new class of epigenetic drugs could significantly reduce scarring in the cells of patients with scleroderma.
Free Cooler. Join for Life.